A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

440

Participants

Timeline

Start Date

March 2, 2017

Primary Completion Date

June 30, 2020

Study Completion Date

April 12, 2021

Conditions
Gastroesophageal Junction AdenocarcinomaGastric Adenocarcinoma
Interventions
DRUG

Ramucirumab

Administered IV

DRUG

Paclitaxel

Administered IV

DRUG

Placebo

Administered IV

Trial Locations (32)

4114

De La Salle Health Sciences Institute, Cavite City

6000

Cebu Doctors Hospital, Cebu City

6100

Dr. Pablo O. Torre Memorial Hospital, Bacolod

10330

King Chulalongkorn Memoiral Hospsital, Bangkok

Police General Hospital, Bangkok

10400

Rajavithi Hospital, Bangkok

13200

Advanced Medical & Dental Institute HUSM, Kepala Batas, Pulau Pinang

40000

Khon Kaen Hospital, Khon Kaen

50586

Hospital Kuala Lumpur, Kuala Lumpur

59100

University Malaya Medical Centre, Kuala Lumpur

62250

National Cancer Institute, Wilayah Persekutuan

93586

Hospital Umum Sarawak, Kuching

100071

The Fifth Medical Center of PLA General Hospital, Beijing

100142

Beijing Cancer Hospital, Beijing

110001

The First Hospital of China Medical University, Shenyang

130012

Jilin Province Tumor Hospital, Changchun

150081

Harbin Medical University Cancer Hospital, Harbin

200032

Zhongshan Hospital, Fudan University, Shanghai

210002

Nan Jing No. 81 Hospital, Nanjing

210008

Nanjing Drum Tower Hosp Affiliated Hosp of Nanjing Univ Med, Nanjing

210009

Jiangsu Cancer Hospital, Nanjing

300060

Tianjin Medical University Cancer Institute & Hospital, Tianjin

310009

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

310016

Sir Run Run Shaw Hospital, Hangzhou

350001

Fujian Medical University Union Hospital, Fuzhou

410013

Hunan Cancer Hospital, Changsha

430022

Wuhan Union (Xiehe) Hospital, Wuhan

430030

Wu Han Tongji Hospital, Wuhan

450052

First hospital affiliated to Zhengzhou University, Zhengzhou

510060

Sun Yat-sen University Cancer Center, Guangzhou

510080

Guangdong Provincial People's Hospital, Guangzhou

710038

Tang Du Hospital, The Second Teaching Hospital of FMMU, Xi’an

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02898077 - A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer | Biotech Hunter | Biotech Hunter